Panagora Asset Management’s Adamas Pharmaceuticals ADMS Stock Holding History

Panagora Asset Management’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-22,549	Closed	-$58K	–	2825
2020 Q2	$58K	Sell	22,549 -139,255	-86%	-$409K	﹤0.01%	1942
2020 Q1	$468K	Sell	161,804 -139,983	-46%	-$627K	﹤0.01%	1146
2019 Q4	$1.14M	Buy	301,787 +271,987	+913%	+$1.3M	0.01%	1005
2019 Q3	$152K	Buy	+29,800	New	+$184K	﹤0.01%	1709
2018 Q1	–	Sell	-2,930	Closed	-$99K	–	2433
2017 Q4	$99K	Buy	+2,930	New	+$81.8K	﹤0.01%	1879
2016 Q3	–	Sell	-1,459	Closed	-$22K	–	2486
2016 Q2	$22K	Sell	1,459 -5,389	-79%	-$88.8K	﹤0.01%	2154
2016 Q1	$99K	Buy	6,848 +5,389	+369%	+$90.8K	﹤0.01%	1862
2015 Q4	$41K	Buy	+1,459	New	+$24.6K	﹤0.01%	2031

Other funds holding ADMS

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DAM

Deltec Asset Management New York $677M AUM 31.67% 1-Year Est. Return

Panagora Asset Management's ADMS Position: Q3 2020 in Review

Panagora Asset Management sold out of Adamas Pharmaceuticals (ADMS) in Q3 2020, closing a stake of 22,549 shares — an estimated $58K sold.

Panagora Asset Management first reported a position in ADMS in Q4 2015 and held it in 8 quarters. The position peaked at $1.14M in Q4 2019. 63 funds tracked by Wall St. Rank hold ADMS as of Q3 2020.

Panagora Asset Management reported no remaining Adamas Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
Panagora Asset Management sold 22,549 Adamas Pharmaceuticals shares in Q3 2020, an estimated $58K.
Panagora Asset Management first reported a position in Adamas Pharmaceuticals in Q4 2015 and held it in 8 quarters.
Panagora Asset Management's Adamas Pharmaceuticals position peaked at $1.14M in Q4 2019.
63 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q3 2020.

Based on Panagora Asset Management's 13F filing for Q3 2020, filed 13 Nov 2020.